

**HERBAL MEDICINAL PRODUCTS:
QUALITY EVALUATION CONTRIBUTION OF THE EUROPEAN PHARMACOPOEIA
TABLE OF CONTENTS**

Welcome address

Dr. A. Artiges, Director of the EDQM, Council of Europe
Phytotherapy- Contribution and impact in modern medicine
Prof. Dr. med. F. H. Kemper, University of Münster (Münster, Germany)

SESSION I: EUROPEAN HARMONISATION

Role of the European Agency for the Evaluation of Medicines (EMA): The quality guidelines prepared by the Working Party on Herbal Medicinal Products
Mrs K. Brønnum-Hansen, Member of the Working Party on Herbal Medicinal Products (EMA)
Results and methods of work of the European Pharmacopoeia
Prof. Dr. G. Franz and Prof. Dr. A. Vlietinck, Chairpersons of Groups of Experts of the Ph. Eur. on Phytochemistry 13A and 13B
Needs and perspectives from professional associations
Mr J. F. Dechamp, Scientific and Regulatory Affairs Executive, Association of the European Self-Medication Industry (AESGP)
Prof. Dr. med. F. H. Kemper, European Scientific Co-operation on Phytotherapy (ESCOP)
Discussion

SESSION II: VIEWPOINT / EXPERIENCE OF THE NATIONAL LICENSING AUTHORITIES IN THE EVALUATION OF LICENSE APPLICATION

Evaluation of the different kind of dossiers: moving from tradition to new requirements and technologies
Dr. L. Anderson, Medicines Control Agency MCA, (London-Great Britain)
M. A. Sawaya, Agence Française de Sécurité Sanitaire des Produits de Santé AFSSAPS, (St Denis-France)
Mr. K. Reh, Bundesinstitut für Arzneimittel und Medizinprodukte BfArM (Bonn-Germany)
Discussion

SESSION III: SPECIFICATIONS AND MONOGRAPHS OF THE EUROPEAN PHARMACOPOEIA

Microbiological quality of herbal starting materials and herbal pharmaceutical preparations
Dr. L. Kabelitz, Phytolab (Vestenbergsgreuth-Germany)
Contaminations in herbal drugs
Dr. B. Klier, Addipharma GmbH (Hamburg-Germany)
Identification and assay: chromatographic profile, determination of active components and markers as tools for reproducible quality.
Dr. F. Lang, Dr. Willmar Schawbe Pharmaceuticals (Karlsruhe-Germany)
Discussion

SESSION IV: EXTRACTS AND TINCTURES

Monographs of extracts in the European Pharmacopoeia
Prof. Dr. A. Vlietinck and Prof. Dr. G. Franz, Chairpersons of Groups of Experts of the Ph. Eur. on Phytochemistry 13 A and 13 B
Overview of extract production and classification
Dr. K. Helliwell, William Ransom & Son PLC (Hitchin-Great Britain)
Determining criteria for the constant quality of the preparations linked to the safety and efficacy
Dr. F. Soldati, Pharmaton SA (Lugano Bioggio-Switzerland)
Dr. E. Bombardelli, Indena SpA (Milano-Italy)
Standardisation of herbal drug preparations
Dr. F. Gaedcke, Finzelberg GmbH & Co. (Andernach-Germany)
Discussion

SESSION V: ROUND TABLE DISCUSSION ON FUTURE DEVELOPMENTS.

With the participation of representatives from the EMA; Professional associations: Dr. E. Eberwein, AESGP; Mr Mills, ESCOP and the European Pharmacopoeia
Biographical notes
List of participants

Tetanus vaccines for human use

TABLE OF CONTENTS

GENERAL INTRODUCTION

Overview of tetanus toxoids: history and current situation
M. C. Hardegree, MD, Maryland, (USA)

SESSION I: ALTERNATIVE TO DIRECT AND INDIRECT POTENCY CHALLENGE ASSAYS IN ANIMALS

Results from assays using serological methods

- Comparison of methods for potency testing of tetanus toxoid vaccines: development and validation of in vitro serological methods for tetanus vaccines for human and for veterinary use C. F. M. Hendriksen, DVM, PhD, National Institute for Public Health and the Environment, (RIVM), (NL)

- Evaluation of serological assays for potency testing of tetanus component in combined vaccines: results of a collaborative study

Dr R. Winsnes, Senior Scientific Adviser, Norwegian Medicines Control Authority, (SLK), (N)

- Discussion

Consequences for routine batch control in Europe

- Consequences of alternative serological methods for routine batch release in Europe: OMCL's point of view

Dr F. Fuchs, Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS), (F)

- Manufacturer's point of view

Dr K. H. Enssle, Chiron Behring GmbH, (D)

- Discussion

Transfer to regulatory requirements: Panel discussion

SESSION II: ISSUES RELATED TO STANDARDS FOR TETANUS VACCINES ASSAY AND TEST METHODS

Calibration of replacement international standard /European Pharmacopoeia biological reference preparation for tetanus toxoid, adsorbed: WHO - EDQM international collaborative study

Dr D. Sesardic, National Institute for Biological Standards & Control, (NIBSC), (UK)

Need for method-dependent unitage assignment?

Standardisation of tetanus vaccines: Do we need method-dependent unitage assignments

Dr E. Griffiths, Coordinator, Quality Assurance and Safety of Biologicals WHO (CH)

Comparison of in vivo and in vitro methods for determining potency of tetanus and diphtheria components in DTP group of vaccines

Dr S. Jadhav, Serum Institute of India Ltd (IND)

- Discussion

SESSION III: FURTHER DEVELOPMENTS OF ASSAYS FOR TETANUS/DIPHThERIA MONOVALENT & COMBINED VACCINES. GENERAL CONSIDERATIONS

Improvement of immunogenicity assays used for monitoring product consistency

Dr W. Vann, Center for Biologics Evaluation and Research, FDA Bethesda (USA)

Tetanus and diphtheria vaccines potency testing in Canada

Dr G. A. Calver, Bureau of Biologics and Radiopharmaceuticals, Health Canada (C)

Development of in vitro assays for tetanus monovalent and combined vaccines

Dr F. Fuchs, Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS), (F)

Manufacturers' point of view

Dr A. Sabouraud, Aventis Vaccines, (F)

Japanese Experience

Dr M. Takahashi, Dept. of Bacterial and Blood products, National Institute of Infectious Disease (J)

Discussion

SESSION IV: TOWARDS HARMONISATION: FURTHER STRATEGY FOR ASSAY OF COMBINED VACCINES CONTAINING TETANUS/DIPHThERIA COMPONENTS

Exploring the perspectives for single dose assays using data from the collaborative study

Mr A. G. J. Daas, Statistician, EDQM, Council of Europe

Mr A. Akkermans, Statistician, RIVM, (NL)

Alternative and simplified models for tetanus toxoid potency testing- Their application to combined vaccines

Dr R. Dobbelaer, OMCL, (B) Authority responsible for releasing vaccines and member BWP (EMA)

Panel discussion and Conclusions:

With the participation of Prof D. H. Calam; Dr E. Griffiths; Dr R. Dobbelaer; Dr R. Winsnes; Dr W. Vann; Dr M. Duchêne, Smith Kline Beecham (B); Mr P. Castle; Mr J.-M. Spieser

Biographical notes

List of participants

Mycoplasma testing

TABLE OF CONTENTS

Presentation of the EDQM

Mr P. Castle, EDQM, Secretary to the European Pharmacopoeia Commission

General introduction to the mycoplasmas with special reference to molecular genetics, phylogeny and taxonomy

Prof. K.E. Johansson, Department of Bacteriology, National Veterinary Institute (SVA), Uppsala (Sweden)

PCR for the detection of Mycoplasma pneumoniae

Prof. C. Bébéar, Laboratoire de Bactériologie, Université V. Segalen, Bordeaux (France)

Validating PCR against the current Ph. Eur. Mycoplasma test

Mr M. Edgington, Microsafe B.V., Leiden (The Netherlands)

Development, application and problematics of a general PCR method for detection of mycoplasmas in cell cultures

Prof. J. Frey, Institute for Veterinary Bacteriology, Berne (Switzerland)

PCR based on 16S rRNA sequences for detection of mycoplasmas

Prof. K. E. Johansson, Department of Bacteriology, National Veterinary Institute (SVA), Uppsala (Sweden)

The use of PCR as a detection/reading system and potential use of membrane laser scanning cytometry and fluorescence flow cytometry as detection/reading system

Mr M. Edgington, Microsafe B.V., Leiden (The Netherlands)

Mycoplasma testing of serum and trypsin

Dr A. Angulo, RIVM, Bilthoven (The Netherlands)

Problems associated with PCR testing : PCR versus culture

Dr K. Smith, Q-One Biotech Ltd, Glasgow (Great Britain)

The application of culture techniques for mycoplasma detection in biological products and cell cultures

Dr H. M. Windsor, Mycoplasma Experience Ltd, Reigate (Great Britain)

The PCR for veterinary mycoplasmas in the diagnostic laboratory

Dr R. A. J. Nicholas, Bacteriology Department, VLA, Addlestone (United Kingdom)

Transfer of experience with diagnostic techniques to vaccine quality control

Dr A. Angulo, National Institute of Public Health and environment, RIVM, Bilthoven (The Netherlands)

Harmonisation of mycoplasma testing : the work of VICH

Dr J. Derr, Pfizer Global Manufacturing, Lincoln (USA)

Round table discussion : Future developments - prospective regarding PCR test

Biographical notes

Reference documents

List of participants

Certification of suitability

TABLE OF CONTENTS

OPENING REMARKS

Dr. D. H. Calam, Chair, European Pharmacopoeia Commission 3

OBJECTIVES, SCOPE AND OPERATION OF PROCEDURE 5

Summary of objectives and scope of the procedure 5

Dr. A. Artiges, Director of the European Directorate for the Quality of Medicines (EDQM), Council of Europe 7

Looking back at 5 years' experience:

The viewpoints of the parties concerned 15

Rapporteurs

Dr. D. De Kaste, RIVM (The Netherlands), Rapporteur and Chair of the Technical Advisory Board (TAB) for the Certification Procedure 17

Licensing Authorities

Dr. J. L. Robert, Chair of the Joint CPMP/CVMP Quality Working Party, (EMEA) 21

Industries

Mr. M. Bouisset, European Federation of Pharmaceutical Industries Association 27

Dr. C. Oldenhof, Vice-Chairman Active Pharmaceutical Ingredient Committee (APIC), European Chemical Industry Council (CEFIC) 37

Summary of the procedure: description of its various steps 47

Dr. C. Pouget, Principal Scientific Officer Responsible for the Certification Unit (EDQM) Council of Europe 49

Round table discussion 57

European Regulation:

Presentation and discussion on Commission Directive 1999/82/EC 65

Dr. D. H. Calam, Chair, European Pharmacopoeia Commission,
Dr. A. Artiges, Director of the European Directorate for the Quality of Medicines (EDQM), Council of Europe

Dr. J. L. Robert, Chair of the Joint CPMP/CVMP Quality Working Party 67

HOW TO PREPARE YOUR DOSSIERS 71

What a dossier should demonstrate:

The compliance of the substance with the requirements of the European monograph 73

Role of the expert report

Dr. E. Souli , National Drug Organisation, EOF (Greece), Rapporteur for the Certification Procedure	73
Mrs K. Brønnum-Hansen , Danish Medicines Agency, DKMA (Denmark), Rapporteur and member of the TAB for the Certification Procedure	77

**Constitution of a dossier: critical points and recapitulation
of the most common deficiencies 83**

Manufacturing method and quality control during manufacture	
Dr. W. Schlumbohm , BfArM (Germany), Rapporteur and member of the TAB for the Certification Procedure	85
Impurities originating from the route of synthesis and residual solvents	
Dr. M. Robertson , Medicines Control Agency, MCA (Great Britain), Rapporteur and member of TAB for the Certification Procedure, and	
Dr. S-E. Hillver , National Product Agency (Sweden), Rapporteur for the Certification Procedure	96
Assessment of stability data: degradation products-retest period	
Prof. J. P. Fournier , Paris University, School of Pharmacy (France), Rapporteur and member of TAB for Certification Procedure	111

Special cases 117**When the manufacturing is likely to use several manufacturing and /or sites for the same substance**

Dr. E. Roets , Leuven University, Faculty of Pharmacy (Belgium), Rapporteur and member of the TAB for the Certification Procedure	119
---	-----

When various grades of a substance are produced

Dr. S. Steiner , Intercantonal Office for the Control of Medicines, IOCM (Switzerland), Rapporteur and member of the TAB for the Certification Procedure	125
--	-----

Follow-up to certification: Variation and quinquennial renewal

Dr. E. Porqueras , Ministry of Health and Consumer Affairs (Spain), Rapporteur and member of the TAB for the Certification Procedure	130
Ms A. Ambrose , Medicines Control Agency, MCA (United Kingdom), Rapporteur for the Certification Procedure	135

Requirements for Excipients:**Present situation and needs for the Certification Procedure 146****Viewpoint of the International Pharmaceutical Excipients Council (IPEC)**

Dr. B. Carlin , Chairman of the IPEC European Certification Masterfile Committee	147
---	-----

Viewpoint of the Quality Working Party of the European Agency for the Evaluation of Medicines (QWP, EMEA)

Dr. J. L. Robert , Chair of the Joint CPMP/CVMP Quality Working Party	154
--	-----

ROUND TABLE DISCUSSION 157**BIOGRAPHICAL NOTES 173****REFERENCE DOCUMENTS 181**

Commission Directive 1999/82/EC	183
Resolution AP-CSP (98) 2	187
Extract of Pharmeuropa 11.3 (September 1999): Active substance, Excipients	205
FINAL LIST OF PARTICIPANTS	209